VTRS · Viatris Inc
Price
Snapshot
50 fields · last close| Market Cap | $20.71B |
| P/E | — |
| Float | 1.16B |
| Beta | 0.91 |
| Volatility | 22.8% |
| Exchange | NASDAQ |
| Sector | Pharmaceuticals |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 79 |
| Price | 16.99 |
| Change | +0.30% |
| Prev Close | 16.94 |
| Open | 17.22 |
| Day Low | 16.81 |
| Day High | 17.28 |
| Avg Vol | 7 |
| Avg $ Vol | $122.4M |
| 52W High | 18.39 |
| 52W Low | 9.43 |
| 52W Pos | 84.4% |
| From High | −7.61% |
| From Low | +80.17% |
| Max DD 1Y | −19.65% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +3.30% |
| SMA 50 | +1.45% |
| SMA 200 | +15.65% |
| RSI (14) | 55.1 |
| Vol 30D | 30.1% |
| Vol 90D | 32.7% |
| 1Y Range | 9–18 |
| Daily bars | 506 |
| Perf Week | +0.30% |
| Perf Month | −4.02% |
| Perf Quarter | +6.54% |
| Perf Half Y | +16.59% |
| Perf Year | +60.57% |
| Perf YTD | +36.36% |
| Prev Day | +0.30% |
| Clavix | B+ |
| Debt / Eq | 0.98 |
| Curr Ratio | 1.38 |
| Int Cover | -0.4× |
| FCF Margin | 12.5% |
| Rev Growth | +4.9% |
| Profit | Unprofitable |
| Leverage | Moderate |
| Sector rank | 6 / 15 |
What VTRS does
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars.
It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.
In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions.
It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands.
The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin.
Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Clavix risk grade
regraded every trading dayVTRS grades B+, 79 of 100. Steadiest on Macro Resilience (67), most exposed on Price Stability (62, mixed). 3 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 6 of 15 in Pharmaceuticals by Clavix score.
How rough the ride is
| VTRS | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.91 | 0.43 |
| Volatilityannualized | 22.8% | 10.7% |
| Max drawdown, past yearworst peak-to-trough fall | −19.7% | — |
| Typical daily movemedian absolute daily change | 1.05% | — |
| Days beyond ±3%of the last 252 sessions | 2410% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| VTRS | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.91 | 0.43 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| VTRS | |
|---|---|
| 1 week | +0.3% |
| 1 month | −4.0% |
| Year to date | +36.4% |
| 1 year | +60.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| VTRS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 5 Jul |
| Average score0 most bearish, 100 most bullish | 60 |
| Bullish · bearisharticles above 60 · below 40 | 21 · 5 |
| Directionarticles whose tone is improving vs worsening | 21 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| VTRS | |
|---|---|
| Revenue growthyear over year | +4.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Pharmaceuticals
15 companies| Metric | VTRS | Sector spread | Median |
|---|---|---|---|
| Beta | 0.91 | 0.43 | |
| Volatility | 22.8% | 10.7% | |
| Debt / equity | 0.98 | 0.94 | |
| Current ratio | 1.38 | 1.86 | |
| FCF margin | 12.5% | 20.8% | |
| Interest coverage | -0.4× | 5.9× |
Recent news
most recent scored articles · the chip is the article’s score · click to openA federal judge in Pennsylvania declined to let several generic-drug makers, including Mylan and Lannett, split an upcoming price-fixing trial (brought by Humana) into separate phases for liability and damages, opting instead for one trial in front of one jury. The case is the first to go to trial in a broader consolidated lawsuit covering multiple defendants. The article is short and does not provide further details.
Shield Therapeutics will take back full US commercial control of its main product from Viatris, and broker Cavendish reiterated its 'buy' rating on Shield with a 23 pence target price (about 318% above the current ~5.5 pence share price). The article reports no financial terms of the change in arrangement.
Broker Cavendish kept its 'buy' rating on Shield Therapeutics (STX) at a 23 pence target after Shield struck a deal to take full US commercial control of its main product from Viatris. The article does not report any rating, price target or new analyst view on Viatris itself.
UBS said concerns about China's new volume-based procurement policy hurting Viatris are overstated, and the company's China business remains resilient. The article text was cut off before completion.
Recent company developments include FDA approval of the Gwyn Lo contraceptive patch and an agreement to transfer rights to TYRVAYA nasal spray.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals PLC | A- | $16.07B | 17.04 | 0.38 | Compare |
| ZTS | Zoetis Inc | B | $31.87B | 12.03 | 0.69 | Compare |
| ELAN | Elanco Animal Health Inc | B- | $12.20B | — | 1.75 | Compare |
| CORT | Corcept Therapeutics Inc | C- | $12.19B | 216.52 | 0.50 | Compare |
| RPRX | Royalty Pharma PLC | A | $36.73B | 45.07 | 0.38 | Compare |
| AXSM | Axsome Therapeutics Inc | B | $10.91B | — | 0.81 | Compare |
| CRNX | Crinetics Pharmaceuticals Inc | D+ | $9.01B | — | 0.45 | Compare |
| MANE | Veradermics Inc | D- | $4.08B | — | -0.14 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.